EFS Selects Omixon for HLA Typing by NGS

16/01/2020

Omixon announce that their flagship Holotype HLA assay and software solution as well as Monotype HLA configuration for disease association studies for HLA typing by Next Generation Sequencing (NGS) has been selected as the HLA typing solution of choice by the Etablissement Français du Sang (the French National Blood Service,...

Questions of Fragmentation, Size Selection and Read Length

11/06/2018

In her EFI 2018 User Group Meeting presentation, Beatrice Bardy (EFS Grenoble) discussed issues about length of fragments and their influence on result quality, including fragmentation and size selection, ambiguities and false novelties using the Holotype HLA protocol since 2016. Download the full presentation here…

2017: An Omixon Odyssey – A Letter from CEO, Tim Hague

30/01/2017

Dear Customers and Friends of Omixon, After a prosperous finish to 2016, I would like you to be the first to know about three major announcements concerning Omixon’s evolution for 2017, in the HLA community and beyond. First, in the next few weeks, we will be launching Holotype...

Alp Şen Foundation Ignite Registry Typing by NGS in Turkey

27/10/2016

Omixon today announce that Holotype HLA, the world’s leading NGS-based product for HLA genotyping has been selected and implemented by the Alp Şen Foundation in Turkey as the HLA genotyping solution of choice. Supply of Holotype HLA will officially be provided through GenPlus, Omixon’s distributor in Turkey – financial details...

Omixon Announce French Tender Victory

27/01/2016

Omixon today announce that their flagship Holotype HLA assay and software solution for HLA typing by Next Generation Sequencing (NGS) has been selected as the HLA typing solution of choice by the Etablissement Français du Sang (the French National Blood Service, EFS). Omixon won a two-year competitive tender worth...